<DOC>
	<DOCNO>NCT02910258</DOCNO>
	<brief_summary>Patients carry primary secondary myelofibrosis Philadelphia negative MPNs ( PMF/SMF ) treat treat pegylated-interferon ( mostly α2a ) eligible prospective study . Biological clinical parameter collect begin drug use last news . A non-opposition consent form need sign enter study .</brief_summary>
	<brief_title>Interferon-pegyle α2a Efficiency Tolerance Myelofibrosis</brief_title>
	<detailed_description>In centre interested , patient diagnose PMF/SMF treat oral sub-cutaneous drug order reduce clinical symptom biological abnormality belong disease . Pegylated-interferon one good weapon use case . These treatment well know use many year french hematological centre . The investigator collect clinical biological data patient treat pegylated-interferon α2a ( use ) case PMF/SMF order ass efficacity tolerance drug . The prescription product dose responsibility practician . Clinical data collect : disease patient characteristics time diagnosis begin drug use , spleen liver size , presence constitutive symptom , transfusion need . Biological data collect : complete hemogram , CD34+ cell count , allele burden JAK2V617F calreticulin clone DNA sample collect . These data collect avery 3 month two first year every 6 month . The investigator also record adverse side effect significative , concomitant use hematological drug ( cytoreductive treatment , ASE ... ) , modality prescription drug reason stop drug etiology death happen .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Primary secondary Myelofibrosis Prescription pegylated interferon α2a Age &gt; 18 yearsold Other MPNs treat pegylated interferon α2a Patients treat PMF SMF without pegylated interferon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>myelofibrosis</keyword>
	<keyword>pegylated interferon</keyword>
</DOC>